Lung Foundation Australia supports all aspects of lung health from asthma and COPD to pulmonary hypertension and cancer, providing community education and a toll-free patient information and support centre.
The organisation also supports research, develops educational fact-sheets, trains health professionals, and undertakes community awareness activity and advocacy around Australia.
In 2019, GSK supported the following Lung Foundation Australia activities.
Lungs in Action Program Evaluation
A program based around the evidence-based intervention of pulmonary maintenance exercise. This provides people with chronic lung disease the essential need to maintain the gains achieved in Pulmonary Rehabilitation. GSK supported Lung Foundation Australia to undertake an impact evaluation of the Lungs in Action program model in 2019 to determine its effectiveness and the outcomes realised for participants (in line with the Lungs in Action 3 Year Strategic Plan).
Pulmonary Hypertension Program 2019
Providing up-to-date information and education to people impacted by PAH. Expanding the reach of this information and education via digital platforms for people with PAH who live in rural and remote locations. Increasing the awareness of PAH in the community to support early diagnosis
Additionally, in 2019 GSK donated 1,000 each of placebo demonstration Metered Dose Inhalers, Elliptas and Accuhalers to help improve COPD patients' medicine adherence through correct inhaler device technique education.